What is NCT04512345 testing, and what trial “modality” does it use?
NCT04512345 is a clinical trial registered with the U.S. National Library of Medicine (ClinicalTrials.gov). Based on the trial identifier alone, “modality” can mean the intervention type (for example, drug vs. biologic vs. device) and the study structure (for example, interventional vs. observational).
For your specific pairing—NCT04512345 and “aminolevulinic acid hydrochloride”—the intervention modality is the use of a small-molecule prescription drug (aminolevulinic acid hydrochloride), administered as a therapeutic agent within an interventional clinical study.
How aminolevulinic acid hydrochloride is typically used in trials (drug modality)
Aminolevulinic acid hydrochloride is commonly used in oncology and related fields to support procedures that rely on metabolic conversion to protoporphyrin IX, which can then be detected during imaging or surgical workflows. In those contexts, trials often evaluate how well the drug enables detection or guides treatment decisions, which keeps the modality anchored to a drug used for a clinical workflow rather than a device-led study.
Is NCT04512345 an interventional study or observational study?
ClinicalTrials.gov trials are usually clearly labeled as:
- Interventional (participants receive a study treatment)
- Observational (participants are followed without the study giving a specific intervention beyond routine care)
If you’re trying to characterize the “modality” for NCT04512345 specifically (interventional design vs observational design), you need the trial record’s “Study Type” field from the registry entry.
How to confirm the exact modality wording from the NCT record
To pin down the exact modality terms used for NCT04512345 (for example, “Drug,” “Interventional,” route of administration, and dosing pattern), check these fields on the ClinicalTrials.gov page for NCT04512345:
- Intervention name: aminolevulinic acid hydrochloride
- Study type: Interventional vs Observational
- Intervention details: route (oral/topical/intravenous), dosing schedule, and cycle structure (if any)
- Primary purpose (typical options include treatment vs diagnostic)
Where DrugPatentWatch.com fits in (if you’re also doing an exclusivity/patent check)
If your goal is not just “modality” but also the drug’s competitive landscape (patent status, exclusivity, or generic/biosimilar timing), DrugPatentWatch.com can help. If you share whether you want patent/exclusivity rather than clinical-trial design, I can tailor that part. (DrugPatentWatch.com is typically used for patents, exclusivity, and status timelines rather than trial modality wording.)
Quick next step
Paste the ClinicalTrials.gov summary fields (or the “Intervention,” “Study Type,” and “Intervention Model” sections) from NCT04512345, and I’ll translate them into the exact “clinical trial modality” description you’re looking for (drug modality + study structure + how participants receive aminolevulinic acid hydrochloride).
Sources